Perspective Therapeutics (CATX) Return on Capital Employed (2011 - 2026)
Perspective Therapeutics recorded quarterly Return on Capital Employed of 39.04% in Q1 2026, up 13.29% quarter-over-quarter from 45.03% in Q4 2025, and down 813.0% year-over-year from 5.48% in Q1 2025.
Perspective Therapeutics' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 39.04% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 813.0% year-over-year to 39.04%; the TTM figure through Mar 2026 stood at 39.04% (down 813.0% YoY), while the FY2025 annual figure was 41.24%, up 391.0% from the prior year.
- Return on Capital Employed came in at 39.04% for Q1 2026 at Perspective Therapeutics, up from 45.03% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 6.09% in Q1 2022 to a low of 46.24% in Q4 2023.
- A 5-year average of 27.16% and a median of 25.45% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 2012 bps in 2024 and plunged 2610 bps in 2025, its largest moves.
- Perspective Therapeutics' Return on Capital Employed stood at 23.27% in 2022, then tumbled by 99 bps to 46.24% in 2023, then jumped by 44 bps to 26.12% in 2024, then tumbled by 72 bps to 45.03% in 2025, then grew by 13 bps to 39.04% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 39.04%, 45.03%, and 42.07% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 7.36% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 11.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 7.62% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 24.24% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 9.30% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 11.57% |
| 10 | Perspective Therapeutics | 380.23 Mn | 380.23 Mn | - | -39.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.04% |
| Dec 31, 2025 | -45.03% |
| Sep 30, 2025 | -42.07% |
| Jun 30, 2025 | -35.66% |
| Mar 31, 2025 | -30.91% |
| Dec 31, 2024 | -26.12% |
| Sep 30, 2024 | -15.98% |
| Jun 30, 2024 | -15.15% |
| Mar 31, 2024 | -25.45% |
| Dec 31, 2023 | -46.24% |
| Sep 30, 2023 | -32.54% |
| Jun 30, 2023 | -25.45% |
| Mar 31, 2023 | -25.32% |
| Dec 31, 2022 | -23.27% |
| Sep 30, 2022 | -15.68% |
| Jun 30, 2022 | -11.73% |
| Mar 31, 2022 | -6.09% |
| Dec 31, 2021 | -5.03% |
| Sep 30, 2021 | -3.79% |
| Jun 30, 2021 | -1.46% |
| Mar 31, 2021 | -8.54% |
| Dec 31, 2020 | -31.86% |
| Sep 30, 2020 | -49.04% |
| Jun 30, 2020 | -47.91% |
| Mar 31, 2020 | -47.63% |
| Dec 31, 2019 | -49.41% |
| Sep 30, 2019 | -56.40% |
| Jun 30, 2019 | -59.17% |
| Mar 31, 2019 | -65.52% |
| Dec 31, 2018 | -60.58% |
| Sep 30, 2018 | -76.41% |
| Jun 30, 2018 | -111.16% |
| Mar 31, 2018 | -80.54% |
| Dec 31, 2017 | -68.57% |
| Sep 30, 2017 | -60.09% |
| Jun 30, 2017 | -52.56% |
| Mar 31, 2017 | -42.76% |
| Dec 31, 2016 | -37.66% |
| Sep 30, 2016 | -34.21% |
| Jun 30, 2016 | -28.46% |
| Mar 31, 2016 | -25.88% |
| Jun 30, 2014 | -17.84% |
| Mar 31, 2014 | -25.72% |
| Dec 31, 2013 | -52.11% |
| Sep 30, 2013 | -57.84% |
| Jun 30, 2013 | -60.89% |
| Mar 31, 2013 | -52.09% |
| Dec 31, 2012 | -46.23% |
| Sep 30, 2012 | -45.21% |
| Jun 30, 2012 | -52.15% |
| Mar 31, 2012 | -46.31% |
| Dec 31, 2011 | -48.11% |
| Sep 30, 2011 | -48.91% |